



# Saniona

## The company

Saniona is a biopharmaceutical company that focuses on rare diseases because it sees considerable unmet need. In addition, development cycles of medicines for rare diseases may need less time and/or less financial investment than more common disorders\*. Saniona's lead asset is **Tesomet**, which has been developed to treat two rare eating disorders: hypothalamic obesity (HO) and Prader-Willi syndrome (PWS). HO and PWS both have symptoms of morbid obesity and hyperphagia (an insatiable craving for food). Hyperphagia is a potentially life-threatening symptom and has so far lacked effective therapies. Currently, **Tesomet** has reached mid-stage clinical development/trial. On July 26, 2021, Saniona received U.S. FDA Orphan Drug Designation\*\* for Tesomet in Hypothalamic Obesity. Tesomet is also on track to become an innovative treatment for Prader-Willi syndrome. In addition, Saniona owns a library of ion channel modifiers that will help to identify new candidates for other rare diseases.

(\*) <https://saniona.com/about-us/our-strategy/>

(\*\*) According to the US Food and Drug Administration (FDA), an orphan drug is defined as one "intended for the treatment, prevention or diagnosis of a rare disease or condition, which is one that affects less than 200,000 persons in the US" (which equates to approximately 6 cases per 10,000 population) "or meets cost recovery provisions of the act." Source: [en.wikipedia.org/wiki/Orphan\\_drug](https://en.wikipedia.org/wiki/Orphan_drug)

## The market

Obesity is one of the three top social burdens caused by our current lifestyle, according to [a major study published by McKinsey in 2014](#). The worldwide aggregated costs associated with being overweight and/or obese are USD \$2.0 trillion. The number of obese (Body Mass Index or BMI >30) or overweight (BMI >25) people has exceeded 2 billion. This is about 25.32% of the current total population of the planet. There are also significant social costs: 2.8 million out of a total 59 million deaths globally per year are tied to obesity. These economic and social burdens are expected to increase. 41% of the global population are projected to be overweight or obese by 2030. The US is experiencing one of the most dramatic increases in obesity. According to the National Health and Nutrition Examination Survey, more than a third of the US adult population (or roughly 88 million) is now estimated to be obese, with another third being overweight. (Source: Nordea research).

## Where our research differs from others

Our main conclusion is that the primary product, Tesomet, works and the Saniona Company will explore therapeutic uses of Tesomet to cover additional obesity-related issues.

### Legal Disclaimer

#### M.I. Achkasov & Co

This document does not constitute an offer to anyone, or a solicitation by anyone, to make any investments in securities. This document must not be issued, circulated or distributed other than to professional investors. All information herein must be treated as confidential or legally privileged information that is intended for addressee(s) only. You are advised to exercise caution in relation to its contents. If you are in any doubt about any of the contents of the document, you should obtain independent professional advice. This material is presented solely for informational purposes and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. Information is obtained from sources deemed reliable, but there is no representation or warranty as to its accuracy, completeness or reliability. All information is current as of the date of this material and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Third party economic or market estimates discussed herein may or may not be realized and no opinion or representation is being given regarding such estimates. This material may include estimates, outlooks, projections and other "forward-looking statements." Due to a variety of factors, actual events may differ significantly from those presented. Indexes are unmanaged and are not available for direct investment. Investing entails risks, including possible loss of principal. Unless otherwise indicated, returns shown reflect reinvestment of dividends and distributions. Past performance is no guarantee of future results. Investing in foreign securities involves greater risks than investing in local securities, including currency fluctuations, interest rates, potential political instability, restrictions on foreign investors, less regulation and less market liquidity. This summary is not a complete list of the risks and other important disclosures involved in investment process.